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Abstract
Study Objectives—The objective was to evaluate the responsiveness of upper airway muscles
to hypercapnia with and without intrapharyngeal negative pressure during non-rapid eye
movement (NREM) sleep and wakefulness.
Design—We assessed the genioglossal muscle response to CO2 off and on continuous positive
airway pressure (CPAP) (to attenuate negative pressure) during stable NREM sleep and
wakefulness in the supine position.
Setting—Laboratory of the Sleep Medicine Division, Brigham and Women’s Hospital.
Patients or Participants—Eleven normal healthy subjects.
Interventions—During wakefulness and NREM sleep, we measured genioglossal
electromyography (EMG) on and off CPAP at the normal eupneic level and at levels 5 and 10 mm
Hg above the awake eupneic level.
Measurements and Results—We observed that CO2 could increase upper- airway muscle
activity during NREM sleep and wakefulness in the supine position with and without
intrapharyngeal negative pressure. The application of nasal CPAP significantly decreased
genioglossal EMG at all 3 levels of PETCO2 during NREM sleep (13.0 ± 4.9% vs. 4.6 ± 1.6% of
maximal EMG, 14.6 ± 5.6% vs. 7.1 ± 2.3% of maximal EMG, and 17.3 ± 6.3% vs. 10.2 ± 3.1% of
maximal EMG, respectively). However, the absence of negative pressure in the upper airway did
not significantly affect the slope of the pharyngeal airway dilator muscle response to hypercapnia
during NREM sleep (0.72 ± 0.30% vs. 0.79 ± 0.27% of maximal EMG per mm Hg PCO2 ,
respectively, off and on CPAP).
Conclusions—We conclude that both chemoreceptive and negative pressure reflex inputs to this
upper airway dilator muscle are still active during stable NREM sleep.
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INTRODUCTION
Obstructive Sleep Apnea (OSA) is a common disorder characterized by recurrent collapse of
the upper airway leading to repetitive episodes of hypoxemia, hypercapnia, and arousal from
sleep.1,2 This disorder affects 2% to 4% of the middle-aged population3 and is associated
with important adverse consequences for afflicted individuals.4–6 The pathogenesis of OSA
is complicated and is likely due to the combination of an anatomically small pharyngeal
airway7–9 and loss of reflex-driven neuromuscular compensation in pharyngeal dilator
muscles during sleep.10,11 Therefore, it is important to understand the mechanisms
controlling upper airway muscle activity during wakefulness and sleep.
Considerable effort has been exerted to define the stimuli modulating upper airway muscle
activity. Identified variables influencing upper airway muscle activity include inputs from
the chemoreceptors,12,13 the brainstem central respiratory pattern generator,14 vagal input
from lung volume,15,16 a tonic wakefulness drive to the respiratory system,17,18 sex-specific
hormones,19 and intrapharyngeal negative pressure.20,21 Evidence suggests that
intrapharyngeal negative pressure acting via mechanoreceptors primarily in the larynx22,23
leads to substantial increases in upper airway muscle activity.11,24
During wakefulness, chemoreceptor activation has been shown to increase upper airway
muscle activity during normoxic and hyperoxic hypercapnia.12,25 In addition, studies of
patients with laryngectomy or tracheotomy have demonstrated that hypercapnia can increase
upper airway muscle activity without pressure changes in the upper airway.26,27 However,
during non-rapid eye movement (NREM) sleep, it is unclear whether CO2 can increase
upper airway muscle activity and whether any such hypercapnic effect on upper airway
muscle activity requires intrapharyngeal negative pressure. The available literature regarding
the responsiveness of upper-airway muscles to hypercapnia during sleep is inconsistent.
Pillar’s and Stanchina’s physiology studies have shown that the pharyngeal muscles have
little responsiveness to CO2 stimulation alone.2,28,29 However, Berry’s and Worsnop’s
observations have shown that substantial increases in upper airway dilator muscle activity
occur both in normal subjects between the onset of sleep and stable NREM sleep as PCO2
rises and in patients with OSA across an apnea.30,31 One possible explanation for these
conflicting data may be due to the fact that Pillar’s and Stanchina’s studies were completed
with subjects in the lateral posture and Berry’s and Worsnop’s observations were completed
with subjects in the supine posture. However, the actual stimulus to upper airway muscle
activity during these studies was unclear because any increase in upper airway muscle
activity with rising PCO2 could be due to increased chemoreceptor activation or increasing
negative pressure in the airway. Because nasal continuous positive airway pressure (CPAP)
applied to the upper airway leads to a decrement in pharyngeal muscle activity,10 assumedly
by attenuating the negative pressure reflex input, CPAP could be used to evaluate whether
chemoreceptor or negative pressure activation is the primary stimulus to pharyngeal muscle
activity as CO2 is increased. Thus, the application of positive pressure can be used to
dissociate chemoreceptor from negative pressure effects during NREM sleep.
In this study, we used the application of nasal CPAP and the administration of CO2 to study
the upper airway muscle responsiveness to hypercapnia with and without intrapharyngeal
negative pressure during NREM sleep and wakefulness in normal healthy humans.
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METHODS
Subjects
Eleven subjects were initially studied with monitoring of both genioglossus and tensor
palatini muscle activity during sleep and wakefulness. Only 2 of the subjects could maintain
adequate sleep to complete the protocol described below. For subject comfort, we
subsequently discontinued the monitoring of tensor palatini muscle activity and focused the
study on the genioglossus muscle. Eleven healthy subjects (6 men, 5 women) without sleep
complaints finished this study. This sample size was based on preliminary data obtained in
the first 3 subjects who completed this study and a prior study from our laboratory. We
determined that 10 subjects would be required, during NREM sleep with CPAP in place, to
detect a difference of 5% in genioglossal activity during hypercapnia (10 mm Hg above the
awake eupneic level) with 80% power and at the 5% significance level. Thus, 11 subjects
were study. Their mean age was 28.5 ± 2.7 (S.E.M.) years, and their mean body mass index
was 23.9 ± 0.7 kg/m2. Written informed consent was obtained from each subject, with the
protocol having the prior approval of the Human Subjects Committee of the Brigham and
Women’s Hospital. Women were studied during the follicular phase (day 5–11) of their
menstrual cycle, as determined by history.
Equipment and Techniques
Ventilation—Subjects wore a nasal mask (Respironics, Inc., Murraysville, PA) connected
to a heated pneumotachometer (model 3700A, Hans Rudolph Inc., Kansas City, MO) and a
differential pressure transducer (Validyne Corp., Northbridge, CA), calibrated with a
rotameter, for measurement of airflow. Inspiratory and expiratory times were determined
from this signal and it was integrated for calculation of tidal volume and minute ventilation.
The subjects were instructed to breathe exclusively through the nose. This was ensured by
taping the mouth and using an infrared video camera to document that the mouth remained
closed.
Muscle Activation—The genioglossal electromyogram (EMG) was measured with a pair
of unipolar intramuscular electrodes referenced to a single ground, producing a bipolar
recording. Two stainless-steel, Teflon-coated, 30-gauge wire electrodes were inserted
approximately 15 mm into the body of the genioglossal muscle 3 mm lateral to the frenulum
on each side, using a 25-gauge needle. The needles were removed immediately, leaving the
wires in place. This technique has been used previously in our laboratory.22
The raw genioglossal EMG was amplified (Grass Instrument, Quincy, MA), band-pass
filtered (between 30 and 1000 Hz), rectified, and electronically integrated on a moving time
average basis with a time constant of 100 milliseconds (CWE, Inc., Ardmore, PA). To
define maximal EMG for the muscle, subjects were asked to perform 4 maneuvers. They
were instructed to (1) swallow, (2) maximally protrude their tongue against the maxillary
alveolar ridge, (3) inspire maximally against an occluded tube, and (4) suck and blow. Each
maneuver was performed several times, and the maximal EMG recorded during this
calibration was designated as 100%. Electrical zero was then determined, and the
genioglossal EMG was quantified as a percentage of maximal activation for that subject.
Since the genioglossal muscle is an inspiratory phasic muscle, its activation was assessed at
2 points during the respiratory cycle. The tonic activation was defined as the lowest
activation during expiration, the peak activation as the highest activation during inspiration
(i.e.,peak phasic), and the phasic activation as the difference between the peak and tonic
activation.
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Sleep-Wake State—Two channels of electroencephalography (C3-A2, O2-A1), left and
right electrooculograms, and the submental EMG were recorded to document wakefulness
or sleep and score the different sleep stages.32 Subjects were maintained in the supine
position throughout this study, verified by infrared video camera.
Nasal CPAP Application—We sought to determine the CPAP level that yielded the
lowest level of genioglossal EMG during wakefulness. To accomplish this, nasal CPAP was
initially applied (BiPAP® S/T-D, Respironics, Inc.) at 4 cm H2O and increased until the
minimal level of genioglossal EMG was obtained or to a maximum of 8 cm H2O. If no
obvious reduction in genioglossal EMG was discernible, the subjects were studied on 6 cm
H2O. The level of CPAP (mean 6.7 ± 0.1 cm H2O) producing this minimal genioglossal
EMG was then used throughout the protocol (see below).
CO2 Administration, PETCO2, and SaO2 Measurement—PETCO2 was measured
from expired air within the nostril using a calibrated infrared CO2 analyzer (Capnograph/
Oximeter Monitor, BCI, Waukesha, WI) while SaO2 was measured using a pulse-oximeter
probe attached to the index finger (Capnograph/Oximeter Monitor). To assess the
hypercapnic response, the inspired fraction of CO2 was increased using a calibrated gas
source (25% CO2-25% O2-balance N2) bled into the inspiratory line to obtain a PETCO2 of
5 and 10 mm Hg above the eupneic level during wakefulness.
Protocol
Each subject reported to the laboratory at approximately 8:00 PM, having fasted for at least
4 hours. After informed consent was obtained, the sleep-staging electrodes and
intramuscular EMG wires were placed. Subjects then assumed the supine posture in bed, and
the nasal mask and pneumotachograph were attached. Subjects subsequently lay with their
eyes open in this posture and were allowed to acclimatize to the equipment. During
documented wakefulness, data were recorded at 3 PETCO2 levels: the normal eupneic level
and plus 5 and plus 10 mm Hg above the eupneic level. After all signals were recorded for
10 minutes of eupneic respiration, the PCO2 was increased and stabilized for 3 minutes at
each level, after which data were recorded for 3 minutes. These measurements, at all 3
levels, were collected both on and off nasal CPAP (order randomized). After data were
recorded during wakefulness, subjects were allowed to fall asleep. Once the subjects were in
stable NREM sleep (stable 2, 3, and 4), the response to rising CO2 was again assessed. First,
measurements at the eupneic PCO2 level were recorded for 3 minutes. Then, inspired CO2
was increased to elevate the PCO2 to exactly the same levels as were studied during
wakefulness (5 and 10 mm Hg above the awake eupneic level). As the PCO2 rose during
sleep, these levels were +2 to +3 and +7 to +8 mm Hg above the eupneic sleeping PCO2. As
during wakefulness, the subjects were held at the desired PCO2 for a full 3 minutes before
acquiring 3 minutes of data. The CO2 response during NREM sleep was measured both on
and off CPAP with the order (CPAP or no CPAP first) being randomized. If the subjects
awoke during CO2 stimulation, they were returned to room-air breathing, and the data were
discarded. A data set (eupneic and 5 and 10 mm Hg above awake eupneic levels), both on
and off CPAP during wakefulness and stable NREM sleep, were recorded 1 time for each
subject. Of note, even in the “off-CPAP” condition, subjects wore a CPAP mask. Thus,
temperature and flow through the mask were quite similar under the 2 conditions.
Data Recording and Analysis
All signals (Flow, VT, PETCO2, SaO2, electrooculogram, EMG, electrocardiogram, and raw
and moving time-averaged genioglossal EMG) were simultaneously recorded on a 16-
channel Grass model 78 polygraph (Grass Instrument, Astro-Medical Inc, West Warwick,
RI) and a personal computer using an analog-to-digital converter (1401plus, Cambridge
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Electronic Design, Ltd, Cambridge, UK) and data-acquisition software (Spike 2, version
5.03, Cambridge Electronic Design, Ltd). The sampling rate varied from 125 Hz for
respiratory signals to 1000 Hz for the raw EMG. For each recording period (wakefulness
and NREM sleep both on and off CPAP at each PCO2 level), a mean value for ventilation
and EMG was determined. These results were then compared statistically.
All statistical analyses were performed with commercially available software (Excel 2000,
Microsoft; and SigmaStat + Sigmaplot, SPSS, Chicago, IL). All data are presented as means
± S.E.M. unless otherwise stated. Repeated-measures analysis of variance with post hoc
Student Newman-Keuls testing was used to assess the effect of CO2 on both ventilation and
genioglossal EMG during wakefulness and NREM sleep both on and off CPAP. Whenever
data were not normally distributed, Friedman repeated-measures analysis of variance on
ranks was used. Ventilation and genioglossal EMG during wakefulness were compared to
values during sleep using a paired t test at each PCO2 level both on and off CPAP. Standard
linear regression was performed to investigate the relationships both between genioglossal
EMG and PETCO2 and between ventilation and PETCO2, both on and off CPAP during
wakefulness and NREM sleep. Regression slopes were compared between conditions. The
Wilcoxon signed-rank test was used if data were not normally distributed. P < .05 was
considered statistically significance.
RESULTS
Full data sets were acquired in 10 of 11 subjects who finished this study, with inspiratory
phasic genioglossal activation being encountered at all CO2 levels, on and off CPAP, awake
and asleep. Figure 1 shows an example of raw data obtained in 1 individual during stable
NREM sleep off and on CPAP at 3 PETCO2 level: basal breathing and +5 and +10 mm Hg
above the awake eupneic level. As can be seen, genioglossal EMG was increased during
hypercapnia both off and on CPAP during stable NREM sleep. As can be seen in Tables 1
and 2, the PETCO2 values at +5 mm Hg and +10 mm Hg were well matched during
wakefulness and sleep. As expected, the baseline PETCO2 level rose during sleep, as
compared with wakefulness (41.5 ± 0.8 to 45.7 ± 0.7 mm Hg).
Genioglossal EMG Response to CO2 On and Off CPAP
Peak, phasic, and tonic genioglossal EMG; ventilation; and SaO2 at 3 different PETCO2
levels on and off CPAP during stable NREM sleep and wakefulness are shown in Tables 1
and 2. During NREM sleep, peak and phasic genioglossal activity significantly increased
with CO2 stimulation both on and off CPAP, as is seen in Figure 2 and Table 1. Raising the
PCO2 augmented tonic genioglossal EMG during NREM sleep on but not off CPAP. The
application of nasal CPAP significantly reduced peak, phasic, and tonic genioglossal EMG
at all PETCO2 levels during NREM sleep, with the exception of tonic genioglossal EMG at
PETCO2 5 mm Hg above awake eupnia (p = .056). During wakefulness, hypercapnia
significantly increased peak and phasic genioglossal activity both on and off CPAP (Figure
2 and Table 2). Tonic genioglossal EMG increased only on CPAP but not off CPAP under
CO2 stimulation. Comparing on CPAP with off CPAP during waking eupnea, peak, phasic,
and tonic genioglossal EMG significantly decreased after CPAP application, but there were
no differences in genioglossal activity on versus off CPAP at PETCO2 levels 5 and 10 mm
Hg above eupneic breathing.
The slopes of peak genioglossal EMG response to CO2 stimulation during NREM sleep and
wakefulness are shown in Figures 3A and 3B. The slopes of peak genioglossal EMG to CO2
stimulation during NREM sleep were not different on and off CPAP (0.79 ± 0.27% vs. 0.72
± 0.30% of maximal EMG per mm Hg PCO2). During wakefulness, the slopes of peak
genioglossal EMG versus CO2 off and on CPAP were not statistically different (0.84 ±
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0.35% vs. 0.59 ± 0.18% of maximal EMG per mm Hg PCO2, p = .35). Comparing the slopes
of peak genioglossal EMG to CO2 stimulation between wakefulness and NREM sleep, both
on and off CPAP, the slopes were quite similar for each condition (0.84 ± 0.35% vs. 0.72 ±
0.30% of maximal EMG per mm Hg PCO2, p = NS; 0.59 ± 0.18% vs. 0.79 ± 0.27% of
maximal EMG per mm Hg PCO2, p = NS, respectively, off and on CPAP).
Ventilatory Response to CO2 On and Off CPAP
During NREM sleep, both on and off CPAP, hypercapnic stimulation significantly increased
minute ventilation via augmenting tidal volume and raising respiratory rate (with decreased
expiratory time). Similarly, during wakefulness, both on and off CPAP, minute ventilation
increased significantly via rising tidal volume and a higher respiratory rate under CO2
stimulation.
The ventilatory response to CO2 both on and off CPAP during NREM sleep and
wakefulness are shown in Figure 4. NREM sleep significantly reduced the slope of the
hypercapnic ventilatory response (HCVR) both off CPAP (1.52 ± 0.14 vs. 0.73 ± 0.08 L/
min/mm Hg PCO2, p = .001) and on CPAP (1.37 ± 0.15 vs. 1.07 ± 0.07 L/min/mm Hg
PCO2, p = .036). Application of CPAP during NREM sleep significantly increased the slope
of the HCVR (1.07 ± 0.07 vs. 0.73 ± 0.08 L/min/mm HgPCO2, p = .002), but CPAP had
little effect on the HCVR during wakefulness.
DISCUSSION
The results of this study suggest that, in normal subjects, CO2 can modulate upper airway
muscle activity during NREM sleep and wakefulness in the supine position even in the
absence of intrapharyngeal negative pressure. However, application of nasal CPAP
significantly decreased dilator muscle activity at all levels of PETCO2 during NREM sleep,
indicating that the negative pressure reflex is still active. Thus both CO2 via chemoreceptor
stimuli and negative pressure reflex inputs to the upper airway dilator muscles remain active
during stable NREM sleep. However, the absence of negative pressure in the upper airway
did not affect the slope of the response of the pharyngeal airway dilator muscle to
hypercapnia. In addition, this study not only confirms the previous finding that NREM sleep
shifts the HCVR to the right and downward,33 but also demonstrates that CPAP application,
during NREM, shifts the HCVR to the left and upward, likely a result of decreasing upper
airway resistance.
Previous work has suggested that chemoreceptor activation substantially modulates upper
airway dilator muscle activity during sleep, while other studies have indicated no effect. For
example, Badr and colleagues34 reported that, in 7 normal subjects, hypercapnia increased
genioglossal muscle activity during NREM sleep in the supine position. On the other hand,
Pillar et al28 investigated genioglossal muscle responsiveness to hypercapnia during NREM
sleep and reported no significant increase in muscle activity. Similarly, Stanchina and
coworkers29 reported that neither inspiratory resistive loading nor normoxic hypercapnia
alone could augment genioglossal muscle activity during NREM sleep. However, both of
these 2 studies were conducted with subjects in the lateral decubitus position. These
conflicting data may be attributable to not only different body positions, but also activating
both chemoreceptors and mechanoreceptors simultaneously as more negative pressure is
generated in the supine airway. Finally, Malhotra and colleagues35 examined postural
effects on genioglossal muscle responsiveness to mechanical stimuli (pulses of negative
pressure) during wakefulness and NREM sleep and reported an increase in genioglossal
muscle responsiveness to negative pressure stimuli during sleep, as compared with
wakefulness, in the supine position but a decrease in the lateral one. Therefore, we
speculated that the genioglossal muscle becomes more responsive to stimuli when the
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pharyngeal airway is more vulnerable or when tongue protrusion is critical to prevent
pharyngeal closure. One potential method of interpretation for the present study is that
CPAP reduces the vulnerability of the pharyngeal airway to collapse, rather than simply
removing the negative pressure stimulus. Thus, not only CO2, but also pharyngeal airway
mechanics (negative pressure, posture, or both) may influence the response of the
genioglossal muscle to hypercapnic stimulation.
With the application of CPAP to minimize intrapharyngeal negative pressure, the
genioglossus muscle could still respond to hypercapnia in the supine position during NREM
sleep, suggesting that the muscle is controlled by respiratory neurons via chemoreceptor
stimuli. We also observed that genioglossal activity decreased when CPAP was applied at
all levels of PETCO2 during NREM sleep. However, the slopes of the genioglossal EMG
response to hypercapnia on and off CPAP during NREM sleep were parallel, indicating that
CO2 was the primary stimulus to muscle activation as PCO2 levels rose. That being said, if
one examines the effect of CPAP on the slope of the genioglossal EMG/CO2 relationship
during wakefulness (Figure 3a) versus sleep (Figure 3b), there are apparent differences.
There is a greater drop (to a lower EMG) in the entire relationship during NREM sleep, as
compared with wakefulness, that is probably a product of the elimination of higher
intrapharyngeal negative pressures by CPAP during sleep, compared with wakefulness. On
the other hand, during wakefulness, there is a trend (not significant) for the EMG/CO2 slope
to become steeper when CPAP is removed. This may indicate greater muscle responsiveness
to intrapharyngeal negative pressure during wakefulness than during asleep.
The finding that sleep was associated with a decrease in the HCVR confirms previous
observations.33 The magnitude of the reduction was also similar. Application of CPAP did
not change the slope of the HCVR during wakefulness, also confirming the previous work
by Browne and coworkers.36 During NREM sleep, CPAP did significantly increase the
HCVR, probably as a result of reducing the elevated upper-airway resistance associated with
sleep. However, even on CPAP, the HCVR was significantly decreased during sleep.
Therefore, these results suggest that both the sleep-induced increment in upper airway
resistance and loss of wakefulness itself impact the ventilatory response to CO2
stimulation.37
Despite its strengths, there are some potential limitations to this study. First, our ultimate
goal is to provide insights into the pathogenesis of OSA. By studying only normal subjects,
any conclusion regarding patients with OSA is speculative. However, patients with OSA are
unlikely to achieve stable NREM sleep without CPAP, limiting the feasibility of the present
study in people with this disease. In addition, an advanced understanding of normal upper
airway dilator muscle control will ultimately improve our knowledge of the pathogenesis of
OSA. Second, stable NREM sleep was selected for this study because hypercapnic
stimulation cannot be meaningfully assessed during wake-sleep transitions due to their
transient nature. Although assessment during rapid eye movement sleep is potentially
achievable, it was not attempted in this study. Third, the application of nasal CPAP causes
additional physiologic changes other than simply lowering upper airway resistance and
eliminating intrapharyngeal negative pressure. These include an increase in resting lung
volume, as well as a potential change in pharyngeal airway shape.38,39 Hemodynamics can
be affected as well. Therefore, the effects of CPAP are probably more complicated than the
simplified view presented here. Multiple studies, including several from our group, have
shown that increasing lung volume decreases upper-airway resistance with a subsequent
decrement in genioglossal EMG.40 Thus, the decrease in genioglossal EMG with CPAP
could have multiple sources (decreased intrapharyngeal negative pressure or increased lung
volume). Moreover, pharyngeal mechanoreceptors may respond to pressure changes rather
than absolute values of pressure, implying that negative pressure stimulation may still occur
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while subjects are on CPAP. However, application of CPAP during NREM sleep
substantially decreases muscle activity at all levels of PETCO2. Thus, although pressure
fluctuations above 0 cm H2O may influence muscle activity, this in no way invalidates the
observations of this study. Thus, we achieved our goal with CPAP, which was to dissociate
mechanoreceptive and chemoreceptive mechanisms. Fourth, we have reported the
responsiveness of only 1 upper airway dilator muscle, the genioglossus, in this study. We
believe that there are substantial data supporting the importance of this muscle in the
maintenance of upper airway patency. However, its behavior may be different from that of
other upper airway muscles, such as the tensor palatini, a tonic upperairway muscle having
less respiratory-related activity and less response to chemical and mechanical stimuli.41
Accordingly, our findings in this study may not reflect the activity of all pharyngeal airway
muscles. Finally, we studied muscle activity at fixed levels of CO2 rather than conducting a
more-standard progressive response. We used this method because it allowed us to establish
steady-state conditions of elevated CO2, allowing careful wakesleep comparisons. Thus, we
believe this to be a valid approach. Despite these potential limitations, we believe that our
findings are credible and that this study advances our understanding of apnea
pathophysiology.
In summary, we have observed that CO2 modulates upper airway muscle activity during
NREM sleep and wakefulness in the supine position in normal subjects even without
intrapharyngeal negative pressure. Application of nasal CPAP significantly decreased dilator
muscle activity at all levels of PETCO2 during NREM sleep, indicating that this negative
pressure reflex is active during NREM sleep. Thus, both chemoreceptor stimuli and negative
pressure reflex inputs to this upper airway dilator muscle remain active during stable NREM
sleep. As a result, this dilator muscle can respond to the challenges imposed by pharyngeal
collapse (partial or complete) during NREM sleep. Thus, the ability of patients with OSA to
maintain stable airway patency some of the time during sleep may reflect these muscle
responses.
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Figure 1.
Individual raw data traces from 1 subject at 3 end-tidal PCO2 (PETCO2) levels: basal
breathing and +5 and +10 mm Hg above awake eupneic level during stable non-rapid eye
movement (NREM) sleep both off and on continuous positive airway pressure (CPAP).
Carbon dioxide (CO2) can increase genioglossal muscle activity both off and on CPAP
during stable NREM sleep. Note that the inspiratory increment in the PCO2 trace at 10 mm
Hg above eupnea both on and off CPAP indicates CO2 accumulation in the inspiratory line
during expiration. GGEMG refers to genioglossal electromyogram; EEG,
electroencephalogram; TV, tidal volume.
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Figure 2.
Bar graphs show the mean (± S.E.M.) peak genioglossal electromyogram (GGEMG)
response to CO2 stimulation at 3 end-tidal PCO2 (PETCO2) levels during wakefulness and
non-rapid eye movement (NREM) sleep both on and off continuous positive airway pressure
(CPAP). CPAP significantly decreases GGEMG at all levels of PCO2 during NREM sleep
but only at the eupneic level during wakefulness. During wakefulness and NREM sleep,
both on and off CPAP, the genioglossal muscle can significantly respond to CO2
stimulation. •P < .05, off vs on CPAP; *P < .05, eupneic vs 5 mm Hg above eupneic levels;
†P < .05, eupneic vs 10 mm Hg above eupneic levels; ‡P < .05, 5 mm Hg vs 10 mm Hg
above eupneic levels.
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Figure 3.
During wakefulness, there is a trend (not significant) for continuous positive airway pressure
(CPAP) to reduce the slope of peak genioglossal electromyogram (GGEMG) response to
CO2 stimulation (A). During non-rapid eye movement (NREM) sleep, on and off CPAP, the
slopes of peak GGEMG response to CO2 stimulation are parallel with CPAP shifting the
curve to the left (B).
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Figure 4.
Both on and off continuous positive airway pressure (CPAP), non-rapid eye movement
(NREM) sleep shifted the waking hypercapnic ventilatory response to the right and
downward. During NREM sleep, CPAP increased the slope of the hypercapnic ventilatory
response.
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Table 1
Ventilation and Muscle Response to CO2 Stimulation during NREM Sleep
Off CPAP On CPAP
Baseline 5 mm Hg 10 mm Hg p Value Baseline 5 mm Hg 10 mm Hg p Value
PETCO2 45.7 ± 0.7 47.1 ± 0.7 51.6 ± 0.6 44.0 ± 0.8 47.1 ± 0.7 51.6 ± 0.7
Genioglossal activity, % max
Peak 13.0 ± 4.9 14.6 ± 5.6 17.3 ± 6.3 .011 4.6 ± 1.6* 7.1 ± 2.3* 10.1 ± 3.1* .005
Tonic 4.4 ± 1.6 5.1 ± 1.9 5.4 ± 1.8 .273 1.9 ± 0.7* 2.6 ± 0.8 3.4 ± 1.2* .036
Phasic 8.6 ± 3.5 9.4 ± 4.0 11.9 ± 4.8 < .001 2.7 ± 1.0* 4.5 ± 1.7* 6.8 ± 2.3* < .001
TI, s 1.8 ± 0.1 1.8 ± 0.1 1.7 ± 0.1 .06 1.6 ± 0.1* 1.6 ± 0.1* 1.5 ± 0.1* .307
TE, s 2.5 ± 0.2 2.5 ± 0.1 2.3 ± 0.1 < .001 2.8 ± 0.2* 2.6 ± 0.1 2.3 ± 0.1 < .001
RR, breath/min 14.2 ± 0.6 14.5 ± 0.6 15.3 ± 0.6 < .001 14.0 ± 0.6 14.7 ± 0.5 15.8 ± 0.5 < .001
TV, L 0.4 ± 0.0 0.5 ± 0.0 0.7 ± 0.0 < .001 0.4 ± 0.0* 0.5 ± 0.0 0.8 ± 0.1* < .001
VE, L/min 6.0 ± 0.2 6.9 ± 0.3 10.5 ± 0.6 < .001 5.1 ± 0.3* 7.5 ± 0.5 13.2 ± 0.8* < .001
SaO2, % 96.5 ± 0.2 97.1 ± 0.2 97.6 ± 0.3 < .001 96.8 ± 0.3 97.3 ± 0.3 97.6 ± 0.3 < .001
NREM refers to non-rapid eye movement; CPAP continuous positive airway pressure; PETCO2 end-tidal PCO2; Peak, highest activity of
genioglos-sus during inspiration; Tonic, lowest activity of genioglossus during expiration; Phasic, difference between genioglossal peak and tonic;
Ti, inspira-tory time; Te, expiratory time; RR, respiratory rate; TV, tidal volume; VE, minute ventilation; SaO2, O2 saturation.
*p < .05, off CPAP vs on CPAP
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Table 2
Ventilation and Muscle Response to CO2 Stimulation during Wakefulness
Off CPAP OnC PAP
Baseline 5 mm Hg 10 mm Hg P Value Baseline 5 mm Hg 10 mm Hg P Value
PETCO2 41.5 ± 0.8 46 4 ± 0.7 51.6 ± 0.7 40.5 ± 1.0* 46.3 ± 0.6 51.6 ± 0.7
Genioglossal activity, % max
Peak 7.8 ± 2.1 12.0 ± 3.6 17.4 ± 5.4 < .001 5.2 ± 1.4* 9.1 ± 2.1 12.5 ± 3.1 .003
Tonic 2.3 ± 0.4 2.5 ± 0.5 2.9 ± 0.6 .067 1.4 ± 0.3* 2.9 ± 0.6 2.9 ± 0.8 .02
Phasic 5.6 ± 1.8 9.5 ± 3.3 14.5 ± 4.8 < .001 3.8 ± 1.3* 6.9 ± 1.8 9.6 ± 2.8 .001
TI, s 1.5 ± 0.1 1.5 ± 0.1 1.8 ± 0.3 .336 1.5 ± 0.1 1.5 ± 0.1 1.6 ± 0.1 .761
TE, s 2.2 ± 0.1 1.9 ± 0.1 1.9 ± 0.2 .029 2.7 ± 0.2* 2.2 ± 0.1* 2.1 ± 0.2 < .001
RR, breath/min 16.7 ± 0.7 18.1 ± 0.9 18.5 ± 1.5 .086 15.1 ± 0.7* 17.0 ± 1.0 17.3 ± 1.2 .035
TV,L 0.4 ± 0.0 0.8 ± 0.1 1.3 ± 0.1 < .001 0.4 ± 0.0* 0.9 ± 0.1 1.2 ± 0.1 < .001
VE, L/min 7.3 ± 0.3 13.8 ± 0.5 22.8 ± 1.4 < .001 6.0 ± 0.4* 14.1 ± 1.0 21.0 ± 1.6 < .001
SaO2, % 97.4 ± 0.3 98.1 ± 0.2 98.1 ± 0.2 .012 97.7 ± 0.3 98.3 ± 0.2 98.1 ± 0.2 .006
CPAP refers to continuous positive airway pressure; PETCO2 end-tidal PCO2; Peak, highest activity of genioglossus during inspiration; Tonic,
lowest activity of genioglossus during expiration; Phasic, difference between genioglossal peak and tonic; Ti, inspiratory time; Te, expiratory time;
RR, respiratory rate; TV, tidal volume; VE, minute ventilation; SaO2, O2 saturation.
*p < .05, off CPAP vs on CPAP
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